Indoco Remedies Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

 Indoco Remedies announced final approval of Allopurinol Tablets USP, 200 mg through Company's Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP to market a generic equivalent to the reference listed drug (RLD), ZYLOPRIM 200 mg of Casper Pharma LLC from USFDA.

Powered by Capital Market - Live News

Allopurinol is used to prevent or lower high uric acid levels in the blood. It is also used to prevent or lower excess uric acid levels caused by cancer medicines or in patients with kidney stones.

The drug is the generic equivalent of the reference listed drug (RLD), Zyloprim, marketed by Casper Pharma LLC.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs).

The pharmaceutical company reported a standalone net loss of Rs 10.23 crore in Q3 FY25 as against a net profit of Rs 20.01 crore posted in Q3 FY24. Revenue from operations stood at Rs 364.91 crore in the third quarter of FY25, down 18.61% as against Rs 448.38 crore posted in Q3 FY24.

Powered by Capital Market - Live News

Net loss of Indoco Remedies reported to Rs 40.39 crore in the quarter ended March 2025 as against net profit of Rs 22.70 crore during the previous quarter ended March 2024. Sales declined 12.57% to Rs 383.89 crore in the quarter ended March 2025 as against Rs 439.08 crore during the previous quarter ended March 2024.

For the full year,net loss reported to Rs 73.74 crore in the year ended March 2025 as against net profit of Rs 98.47 crore during the previous year ended March 2024. Sales declined 8.22% to Rs 1641.29 crore in the year ended March 2025 as against Rs 1788.22 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Indoco Remedies announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 0.2 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News